Brave Asset Management Inc. Sells 1,767 Shares of Pfizer Inc. (NYSE:PFE)

Brave Asset Management Inc. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 6.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,418 shares of the biopharmaceutical company’s stock after selling 1,767 shares during the period. Brave Asset Management Inc.’s holdings in Pfizer were worth $648,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Lmcg Investments LLC increased its holdings in shares of Pfizer by 1.1% in the second quarter. Lmcg Investments LLC now owns 51,777 shares of the biopharmaceutical company’s stock valued at $1,449,000 after purchasing an additional 543 shares during the last quarter. Pekin Hardy Strauss Inc. grew its stake in Pfizer by 8.4% in the 2nd quarter. Pekin Hardy Strauss Inc. now owns 27,095 shares of the biopharmaceutical company’s stock valued at $758,000 after buying an additional 2,090 shares during the last quarter. Edgestream Partners L.P. raised its holdings in Pfizer by 1,704.3% in the 2nd quarter. Edgestream Partners L.P. now owns 157,967 shares of the biopharmaceutical company’s stock valued at $4,420,000 after acquiring an additional 149,212 shares during the period. Perennial Investment Advisors LLC lifted its position in Pfizer by 9.6% during the second quarter. Perennial Investment Advisors LLC now owns 15,549 shares of the biopharmaceutical company’s stock worth $435,000 after acquiring an additional 1,358 shares during the last quarter. Finally, Lumbard & Kellner LLC boosted its holdings in shares of Pfizer by 8.0% during the second quarter. Lumbard & Kellner LLC now owns 113,901 shares of the biopharmaceutical company’s stock worth $3,187,000 after acquiring an additional 8,454 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Price Performance

Shares of PFE stock opened at $26.25 on Thursday. The business has a fifty day simple moving average of $26.13 and a 200 day simple moving average of $28.03. The company has a market cap of $148.76 billion, a P/E ratio of 35.47, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.17) earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.55%. Pfizer’s dividend payout ratio is 227.03%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on PFE shares. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Citigroup began coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.